The existence of the J-curve in hypertension treatment remains controversial. The major question is whether the increase in mortality from coronary disease is induced by the lowering of blood pressure (BP) or by the severity of underlying coronary artery disease. We recruited patients with a history of hyperten- Even this well-organized study, however, could not fully disprove the existence of a J-curve (3).
Introduction
Lowering elevated blood pressure levels decreases cardiovascular morbidity and mortality. However, the optimal levels of blood pressure (BP) or treatment targets are still controversial. Cruickshank et al. reported a J-curve relationship between increased mortality and an achieved diastolic BP (DBP) of below 85 mmHg in patients with pre-existing ischemic heart disease (1) . In contrast, the results of the Hypertension Optimal Treatment (HOT) study demonstrated the benefits of lowering DBP to 82.6 mmHg or lower (2) .
Importantly, the existence of a J-curve has been reported in untreated controls in several hypertension trials (4-7). Coope reported J-curves in both treated and control groups, with the curve in the treated patients being similar in shape but 10 mmHg lower than that in the controls (8) . Thus, one of the major critical issues in regard to the J-curve phenomenon is whether the lower DBP is a result of anti-hypertensive treatment or simply due to the nature of complicated cardiovascular disease. Serious coronary artery disease may lower BP, and itself may be associated with a poor prognosis.
In the present study, we examined hypertensive patients with coronary artery lesions confirmed by coronary angiography who had been given a clinical diagnosis of angina pectoris. The specific question was whether there is a point beyond which BP reduction is no longer beneficial and possibly even deleterious in hypertension with coronary artery disease, and whether the severity of coronary artery lesions modifies the J-curve phenomenon.
Methods

Patients
The present study was approved by the Ethical Committee of Asahikawa Medical College. Patients were recruited from 11 hospitals based on their records from 1992 to 1997. The enrolled patients had history of hypertension (systolic BP (SBP) 160 mmHg and/or DBP 90 mmHg) and had been diagnosed with angina pectoris based on coronary angiography, but had no history of previous myocardial infarction. For all patients, the details of the clinical history and coronary angiographical findings in the hospital records were clinically confirmed upon enrollment. The patients' information, clinical history and clinical consequence were reported on data-record forms, as were the treated levels of blood pressure, and antihypertensive and antianginal drugs used. The listed cardiovascular events (Events) were hospitalization due to unstable condition, required coronary intervention such as percutaneous transluminal coronary angioplasty or coronary arterial bypass graft surgery, myocardial infarction and cardiovascular death. Myocardial infarction and cardiovascular death were additionally recorded as serious cardiovascular events (S-Events).
Assessment of Coronary Artery Lesions
The coronary artery lesions of eligible patients were evaluated by coronary angiography by referring to the anatomical severity of lesions, i.e., the number of diseased vessels and the degree of narrowing of the coronary arterial lumen. The coronary angiographic findings were confirmed by more than two specialists at each hospital. The number of diseased major vessels exhibiting a more than 75% narrowing in luminal diameter was counted and used to divide the patients into four groups: a zero-, single-, double-and triple-vessel disease group. The coronary severity index (CSI) was calculated as the sum of the stenosis lesion grades for each coronary artery, with a grade of 1.0 being given for lesions with more than 90% narrowing in luminal diameter and a grade of 0.5 for lesions with 75-90% narrowing. Coronary spasm was diagnosed by typical anginal attack with ST elevation in ECG and positive provocation test with intracoronary acetylcholine or ergonovine administration in coronary angiography.
Statistics
All patients' data were reported on data-record forms at each hospital, and were sent to the coordinating center at Asahikawa Medical College. 
Results
Patient Characteristics, Achieved Diastolic Blood Pressure and Cardiovascular Events
A total of 234 patients were enrolled, with a mean age of 64 1 years. Eighty-two patients were women, and 79 (96.3%) of them were post-menopause. The average duration of clinical history, i.e., the mean period over which a clinical history could be retrieved from the patients' records, was 11.2 0.7 years for hypertension and 4.3 0.3 years for angina pectoris. Patients were divided into two groups, a group with (Event( ); n 115) and one without (Event( ); n 119) cardiovascular events. The Event( ) group included a subgroup of 19 patients with serious events (SEvent( )), 16 with acute myocardial infarction and 3 with cardiovascular death. No other cause of death was observed during the follow-up of this cohort. Thus, the cardiovascular events of the remaining 96 were hospitalization for unstable condition requiring coronary artery intervention. The average blood pressure on treatment in the Event( ) group, which was calculated by averaging the blood pressures retrieved for the 2 months prior to the start of the study, was 151 2/88 1 mmHg. The average blood pressures in the Event( ) group and S-Event( ) group, which were determined by averaging the blood pressures retrieved for the 2 months prior to the onset of cardiovascular events, were 151 2/87 1 and 153 4/93 3 mmHg, respectively. There were no significant differences in the average blood pressure on treatment among the three groups (Table 1) .
On entry to the study, 160 of 234 patients (68.4%) had been prescribed a calcium antagonist alone or in combina-tion with other drugs: a β-blockade in 10.7%, an angiotensin converting enzyme (ACE) inhibitor in 13.2%, and a diuretic in 4.7%. The frequency of use of each drug was not significantly different between the Event( ) and Event( ) groups. The frequency of use of calcium antagonist was not significantly different among the three event subgroups: 68.1% in Event( ), 68.7% in Event( ) and 63.2% in SEvent( ). The incidence of Events was 48% in the patients treated with a calcium antagonist and 51% in the patients treated without a calcium antagonist, and the difference between groups was not statistically significant. Eighty-eight point five percent of the calcium antagonists used in the study were long acting.
The frequency of smoking was slightly higher in the Event( ) group; however, there were no significant differences in risk factors among groups (Table 1) .
Angina Pectoris and Coronary Artery Lesions
The clinical forms of angina pectoris were classified in three groups: angina pectoris mainly due to organic coronary lesion (n 169), angina pectoris mainly due to coronary spasm (n 49), and mixed forms (n 16). Angina pectoris with coronary spasm was more frequent in the Event( ) than in the Event( ) or S-Event( ) groups ( p 0.05). The incidence of triple vessel diseases was significantly higher in the Event( ) (20.0%) and S-Event( ) (21.1%) than in the Event( ) (11.5%) group ( p 0.05). In contrast, the incidence of zero vessel diseases was significantly higher in the Event( ) (22.7%) than in the Event( ) (12.2%) group ( p 0.05). The CSI in the Event( ) group was 0.97 0.08, which was significantly lower than that in the Event( ) (1.33 0.08; p 0.01) or S-Event( ) (1.42 0.20; p 0.05) groups (Table 1) . Table 2 ). The relationship between the incidence of Events and BP levels was basically similar in shape in both SBP and DBP. However, the subgroup with significantly higher incidence of Events was observed only in SBP. The subgroups of SBP 1124 and 155-169 mmHg showed significantly higher incidence of Events compared to the subgroup of 140-154 mmHg. In contrast, there were no significant differences in the incidence of Events among the five subgroups of DBP. Next, the incidence of S-Events as a function of SBP and DBP was compared among the five subgroups described above (Table 2) . A positive correlation was observed between the incidence of S-Events and DBP, with the lowest incidence of 2.6% occurring in the lowest DBP subgroup of 174 mmHg and the highest incidence of 12.5% occurring in the highest DBP subgroup of ≥105 mmHg (Fig. 1) . Similarly, the highest incidence of serious events was observed in the highest SBP subgroup of ≥170 mmHg. However, the relation assumed a J-shape. The incidence of S-Events gradually decreased with decreasing SBP, reached a nadir at 
Fig. 1. The incidence of serious cardiovascular events including myocardial infarction and cardiovascular death (A) and the coronary severity index (CSI) (B) as a function of diastolic blood pressure (DBP). There was a positive association between DBP and the incidence of serious coronary events, and a reverse J-curve relationship between DBP and CSI in hypertensive patients with angina pectoris.
125-139 mmHg, and increased again at 1124 mmHg.
Coronary Severity Index and Levels of Blood Pressure or Incidence of Events
The CSI was compared among five subgroups of DBP and SBP divided according to the levels of blood pressures as above (Table 2 ). There was a reversed J-shaped relation between the CSI and DBP: the highest CSI of 1.47 0.12 was observed in the subgroup of DBP 174 mmHg and decreased stepwise as DBP increased with a nadir of 0.97 0.12 at 95-104 mmHg, then increased again at 0105 mmHg (Fig. 1) . These relations between the CSI and DBP of patients with SEvents were similar in shape but the CSI component was shifted upward by approximately 0.5. There was a similar reversed J-shaped relation between the CSI and SBP: the highest CSI was observed in the subgroup of SBP 125-139 mmHg and decreased stepwise as SBP increased with the nadir at 155-169 mmHg, then increased again at the SBP subgroup of 0170 mmHg. The CSI in the lowest SBP subgroup of 1124 mmHg was a relatively low 1.13 0.17; however, patients with S-Events had a significantly high CSI of 1.75 0.25. The incidence of Events were compared among three subgroups of CSI: a Low ( 1.0), Middle (1.0 to 2.0) and High (02.0) group. The incidence of Events in the Low CSI subgroup (32.5%) was significantly lower than those in the Middle (54.9%; p 0.01) or High (60.6%; p 0.01) CSI subgroups. In contrast, no statistically significant difference was observed in the incidence of S-Events (Low, 3.9%; Middle, 9.9%; High, 10.6%). There were no significant differences in SBP among the three groups (150 2, 152 2 and 149 3 mmHg, respectively). However, the DBP of the Low CSI subgroup (90 1 mmHg) was somewhat higher than that of the Middle CSI subgroup (87 1 mmHg), and significantly higher than that of the High CSI subgroup (85 2 mmHg) ( p 0.05).
Discussion
This is the first report to investigate the impact of the severity of coronary artery lesions on the relationship between the incidence of cardiovascular events and the treated levels of blood pressure. Several previous reports have demonstrated a J-curve relation between cardiovascular events and DBP in hypertension treatment (1, 9-13); they have not, however, considered the severity of coronary artery lesions.
Cruickshank et al. reported a J-curve phenomenon with an increase in mortality for achieved DBP below 85 mmHg in hypertensive patients with pre-existing ischemic heart disease (1) . However, their definition of ischemic heart disease was not based on the consideration of coronary artery lesions. In the present study, we investigated patients whose coronary lesions had been angiographically confirmed. We could not find a J-point in the vicinity of the DBP range of 85-90 mmHg. There were no significant differences in the incidence of total events among the DBP subgroups. The most important finding we observed was the positive correlation between DBP and the incidence of serious cardiovascular events in hypertensive patients with angina pectoris.
In contrast, the correlation between SBP and the incidence of serious cardiovascular events assumed a J-shape. The Jcurve relation of SBP was reported in the Multiple Risk Factor Intervention Trial (MRFIT) in hypertensive patients with a history of myocardial infarction (9) . This study suggested that low BP soon after myocardial infarction is potentially a consequence of myocardial damage, and predicts a poor prognosis. The possibility of a "reverse causality bias," i.e., the possibility that patients who have serious coronary artery disease and poor cardiac pump function cannot produce a high SBP, may explain the slight increase of events in the lowest subgroup of SBP. In fact, the patients who experienced serious events had high CSI scores in the subgroup of SBP 1124 mmHg.
Although the major risk factors established in Caucasians are also risk factors for coronary arterial lesions in Japanese with hypertension (14) , the severity of coronary artery stenosis and the number of diseased vessels are known determinants of morbidity and mortality in patients with coronary artery disease (15) . As we expected, cardiovascular events were more frequently observed in patients with greater CSI. In other words, the CSI was significantly greater in patients either with total or serious events compared to event-free patients. More importantly, we found a reverse J-shaped curve relation between CSI and BP, particularly in DBP. These results indicate a potential high risk for cardiovascular events in patients with lower BP and greater CSI. However, it was surprising that the lower the DBP the better was the prognosis in terms of serious coronary events, and patients with an SBP of 125-139 mmHg had the greatest CSI but the lowest incidence of serious coronary events. We may speculate that the relatively high incidence of total events in patients with lower BP and greater CSI indicates a higher disease activity of coronary lesions, potentially requiring coronary intervention. However, the higher incidence did not necessarily mean that these patients were subject to serious events, such as myocardial infarction. One, and the most plausible, explanation for these discrepancies is the fact that coronary lesions responsible for acute ischemic events do not necessarily have severe stenosis, but often tend to have only mild-tomoderate stenosis (16) . This conclusion was derived from either sequential angiograms (17, 18) or highly magnified cineangiographic views taken to speculate on the original lesions responsible for the infarction (19) . These previous studies did not investigate hypertension as a specific factor for inducing an acute ischemic event. There is compelling evidence that high shear stress originating from high blood pressure may trigger acute plaque disruption on the coronary arterial wall (20, 21) , which in turn may lead to acute coronary syndrome including unstable angina pectoris, acute myo-cardial infarction and sudden cardiac death (22) . We speculate that higher blood pressure plays a crucial role in inducing coronary events in the hypertensive patients with relatively lower CSI, i.e., mild-to-moderate coronary stenotic lesion. Alterations in vessel-wall stresses on or within plaques are important in their disruption. The greater wall stresses on plaques make them more susceptible to rupture (16) . The wall stress experienced by any blood vessel is directly proportional to intraluminal pressure and vessel radius (23) . Therefore, the smaller wall stress in patients with lower DBP and smaller coronary diameter may contribute to the positive relationship between the level of DBP and the risk of serious events.
One more point that should be discussed is the antihypertensive drugs used in the present study. It is quite possible that the adverse effects of some drugs partly counterbalance any true cardioprotective effects of hypertension treatment. Calcium antagonists are the antihypertensive and antianginal drugs that have been used most frequently in Japan (24) (25) (26) . More than two-thirds of patients were prescribed a calcium antagonist in the present study. Recently, the debate on the potential hazards of calcium antagonists in the treatment of ischemic heart disease and hypertension has been revived (27, 28) . The debate was once concluded with a recommendation against the use of short-acting calcium antagonists, especially short-acting dihydropiridine compounds, in the treatment of ischemic heart disease and hypertension (29) . In the present study, there were no significant differences in the frequency of use of calcium antagonists or any other types of antihypertensive drugs in patients with or without events. Fortunately, nearly 90% of the calcium antagonists used in the present study were long-acting. This may be the reason why the use of calcium antagonists did not affect the prognosis of the present cohort.
Our results are limited by several factors. Because the present study was a retrospective investigation, we could not intentionally control the treated levels of BP, the medication compliance of each patient or the application of coronary intervention. Since the application of coronary intervention was entrusted to doctors in each hospital, an inter-hospital difference in indication of coronary intervention may have affected the prognosis of the studied patients. Frequent coronary intervention may increase the risk of an advanced cardiovascular event. However, thanks to recent medical advancement in coronary intervention (30, 31) , this risk has been greatly reduced. We believe the application of coronary intervention in our hospitals does not deviate from the recent medical standard of treatment of coronary artery disease (32, 33) .
In conclusion, we found a reverse J-curve relationship between DBP and the severity of coronary artery lesion, and a positive association between DBP and serious coronary events in hypertensive patients with angina pectoris. Together with a similar relationship for SBP, this suggests that high BP plays a crucial role in the induction of serious events in patients with moderate coronary artery lesion. Further investigation in a prospective randomized manner will be needed to confirm the optimal BP levels in antihypertensive treatment of hypertensive patients with coronary artery disease.
